Different Doses of Tyrosine Adsorbed Grass Pollen Allergoid With Monophosphoryl Lipid A (MPL) in Patients Sensitized to Grass Pollen
A Double-Blind Phase IIb Study to Evaluate the Safety and Efficacy of Different Doses of Tyrosine Adsorbed Grass/Rye Pollen Allergoid With MPL in Patients Sensitized to Grass and Rye Pollen
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
Mississauga, Ontario, Canada, L4W 1N2
- Allied Research International Inc.
-
Mississauga, Ontario, Canada, L5B 1N1
-
Ottawa, Ontario, Canada, K1Y 4G2
- Ottawa Allergy Research Corporation
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- positive skin prick test for grass and rye allergen
- Specific IgE for grass and rye as documented by radioallergosorbent or equivalent test with class >= 2
- History of at least 1 season of moderate to severe seasonal rhinoconjunctivitis due to an IgE - mediated allergy to pollen from grass and rye
- Males or non-pregnant, non-lactating females who are post-menopausal or naturally or surgically sterile. Females of childbearing potential have a confirmed absence of pregnancy according to a negative urine pregnancy test and must be using an acceptable birth control method.
- Spirometry at Screening demonstrates FEV1 >= 80% predicted and FEV1/FVC >= 70%
Exclusion Criteria:
- Acute or subacute atopic dermatitis and/or urticaria factitia and/or urticaria due to physical or chemical influence and/or chronic dermatitis
- Patient has moderate to severe asthma
- Visual inspection of the forearms indicates potential problems with the conduct or interpretation of the skin prick test; both forearms must be available for testing
- History or presence of diabetes, cancer or any clinically significant cardiac, metabolic renal, hematologic diseases or disorders
- Recent clinically significant history (within 2 years) of hepatic gastrointestinal, dermatologic, venereal, neurologic or psychiatric diseases or disorders
- Any clinically significant (as determined by the investigator) abnormal laboratory value
- Perennial allergens: clinically relevant sensitivity against house dust mites, molds, and epithelia
- Patient has clinically relevant sensitivity against the following summer/autumn season flowering plants: plantain, orache, nettle, mugwort, Bermuda grass, or ragweed.
- Secondary alteration at the affected organ
- History of autoimmune diseases and/or rheumatoid diseases
- Patient is taking b-blockers
- Patient who is not allowed to receive adrenalin
- Patients in whom tyrosine metabolism is disturbed
- Presence of a disease with a pathogenesis interfering with the immune response and patient has received medication which could influence the results of this study
- Documented evidence of acute or significant chronic infection
- History of anaphylaxis
- Documented history of angioedema
- Hypersensitivity to excipients in the study medications
- Previous or current immunotherapy with comparable grass/rye allergen extracts
- Currently using anti-allergy medication and other drugs with antihistaminic activity
- Patients currently participating in a clinical trial or who have been exposed to study medication within the last 30 days
- Patient is pregnant or planning pregnancy and/or lactating
- Patient has received treatment with preparation containing MPL® during the past 12 months
- Any systemic disorder that could interfere with the evaluation of the study medication(s)
- Clinical history of drug or alcohol abuse that would interfere with the patient's participation in the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
immunological response to the three GrassMATAMPL treatment arms compared to placebo (grass specific)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
number of adverse events
|
|
number of adverse reactions
|
|
tolerability of different subcutaneous doses
|
|
tolerability of the cumulative subcutaneous doses
|
|
clinical chemistry and hematology
|
|
immunological response to the three GrassMATAMPL treatment arms compared to placebo (rye specific)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Kemi Oluwayi, MD, Allergy Therapeutics
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- GrassMATAMPL203
- P2DP5005
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.